The Mission Report

Biotech Showcase™ 2016

January 11 - 13, 2016

San Francisco


Biotech Showcase™ is an investor and networking conference that provides private and public biotechnology and life sciences companies with an opportunity to present, build their profile, conduct one-to-one meetings, and network with investors and pharmaceutical executives – all during the course of one of the industry's largest annual healthcare investor conferences. Now in its eighth year, BTS 2016 is expected to attract more than 2,100 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies. BTS 2016 takes place January 11-13, 2016, in San Francisco. For more information about EBD Group's BTS conference, visit


Antisense Therapeutics Ltd. (ATHJF)

Antisense Therapeutics Ltd. (OTC: ATHJF) is an Australian pharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics. One of Antisense Therapeutics' fundamental strategies is acquiring access to state of the art antisense technology, in both know-how and intellectual property, to accelerate drug discovery and development. For more information, visit the company's website at

Arch Therapeutics (ARTH)

Arch Therapeutics (NASDAQ: ARTH), a medical device company, offers an innovative approach to rapid cessation of bleeding and control of fluid during surgery and trauma care. The underlying technology, exclusively licensed from a leading university, supports an innovative platform of smart materials that fulfill the criteria as a solution for a specialized field called: stasis and barrier applications. For more information, visit the company's website at

Asterias Biotherapeutics, Inc. (AST)

Asterias Biotherapeutics, Inc. (NYSE: AST) is engaged in the emerging field of regenerative medicine. The company's proprietary platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias' portfolio includes: AST-OPC1, currently in a phase 1/2a dose escalation clinical trial in spinal cord injury; AST-VAC1, which has demonstrated promise in a phase 2 study in acute myelogenous leukemia; and AST-VAC2, which represents a second generation, allogeneic approach to dendritic cell vaccines. For more information, visit the company's website at

Aytu BioScience, Inc. (AYTU)

Aytu BioScience, Inc. (OTC: AYTU) is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. Aytu is initially concentrating on prostate cancer, male sexual dysfunction and male infertility and plans to expand into other urological indications for which there are significant medical needs. The company currently markets ProstaScint® (Capromab Pendetide), the only radioimaging agent indicated to detect prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. For more information, visit the company's website at

Benitec Biopharma (BNTC)

Benitec Biopharma (NASDAQ: BNTC) has developed a breakthrough platform for treating human diseases called DNA-directed RNAi (ddRNAi). Unlike other RNAi-based technologies, ddRNAi effects lasting change in target cells, leading to long term benefits and, potentially, a cure. The company thus holds the dominant global patent position for expressed RNA interference, placing it in a commanding position for human therapies associated with specific genes and genetic disorders. The use of shRNA for use in humans also falls under the company's patent estate. For more information, visit the company's website at

BioLife Solutions, Inc. (BLFS)

BioLife Solutions, Inc. (NASDAQ: BLFS) is located in Bothell, Washington, on a high-tech campus that has roots as a dairy farm. The company manufactures and markets proprietary protein-free, serum-free cGMP biopreservation media for cells, tissues and organs. BioLife Solutions performs contract R&D and offers consulting to optimize customer-specific biopreservation protocols and processes. And for its direct, distributor and contract customers, it provides custom formulation, fill and finish services. For more information, visit the company's website at

Bionik Laboratories Corp. (BNKL)

Bionik Laboratories Corp. (OTC: BNKL), a medical device and robotics company, focuses on robotic exoskeleton technology for those with mobility impairments. The technology gives users a chance to rehabilitate effectively by being able to walk. Bionik Laboratories has researched, developed and tested its primary product, The ARKE™, an exoskeleton device that allows paraplegics and other mobility impaired individuals to stand up, walk and rehabilitate in a more effective way than current rehabilitation methods. For more information, visit the company's website at

Biosig Technologies, Inc. (BSGM)

Biosig Technologies, Inc. (OTC: BSGM) is a development stage medical device company that engages in developing technology platforms for the purposes of reducing noise from cardiac recordings during electrophysiology studies. The company's main product under development is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP system, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. For more information, visit the company's website at

Ceapro, Inc. (CRPOF)

Ceapro, Inc. (OTC: CRPOF) is a Canadian biotechnology company with headquarters in Edmonton, Alberta. Through the use of proprietary technology and renewable and sustainable resources, Ceapro is focused on becoming a global leader in developing and commercializing functionally active ingredients for human and animal health markets. The company has already achieved a reputation as an innovative formulator and advanced processor of unique natural-based products supported by strong science and clinical evidence. For more information, visit the company's website at

Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is developing agents to detect, treat and monitor a broad spectrum of cancers. With the ability to attach imaging and therapeutic agents to its proprietary delivery platform – a novel phospholipid ether (PLEs) platform technology that is a targeted delivery and retention vehicle, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer cells to "find, treat and follow" malignancies in a highly selective way. For more information, visit the company's website at

Cellular Biomedicine Group (CBMG)

Cellular Biomedicine Group (NASDAQ: CBMG) is a biomedicine company principally engaged in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. The company is focused on developing and marketing safe and effective cell-based therapies based on its cellular platforms that represent a large unmet need in China, such as cancer, orthopedic diseases (including osteoarthritis and tissue damage), various inflammatory diseases and metabolic diseases. For more information, visit the company's website at

Chembio Diagnostics, Inc. (CEMI)

Chembio Diagnostics, Inc. (NASDAQ: CEMI) is committed to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). At the core of its commitment is its patented Next Generation DPP (Dual Path Platform) technology, a breakthrough in POC diagnostics, offering significant advantages over lateral-flow technologies including: significantly improved sensitivity; multiplexing – multiple test results via a single blood sample (e.g., HIV-Syphilis Assay); and application in a number of indications. For more information, visit the company's website at

Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals, Inc. (OTC: CTXR) is a pharmaceutical company developing and commercializing therapeutic products for large and growing markets. Citius uses approved drugs with substantial safety and efficacy data in an effort to reduce the risks associated with pharmaceutical product development. Citius' first FDA-approved product, Suprenza, is a novel formulation of a leading obesity drug. Citius' is also advancing a product candidate for the treatment of hemorrhoids. Citius utilizes FDA's 505(b)(2) pathway for our new drug approvals. For more information, visit the company's website at

ContraFect Corp. (CFRX)

ContraFect Corp. (NASDAQ: CFRX) is a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. The company is finding answers to drug-resistant and newly-emerging pathogens that are responsible for hospital-based infections, the fourth leading cause of death in the U.S., and developing powerful new molecular treatments to kill these deadly microbes, which become resistant through mutation and cause worldwide pandemics, and to revolutionize medicine. For more information, visit the company's website at

ContraVir Pharmaceuticals (CTRV)

ContraVir Pharmaceuticals (NASDAQ: CTRV) is developing targeted antiviral therapies with two drug candidates in clinical studies. The first drug candidate, FV-100, is now in phase 3 trials. It is being developed for the treatment of herpes zoster, or shingles, and shingle pain. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread). For more information, visit the company's website at

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage drug development company targeting rare, chronic and serious inflammatory and fibrotic diseases with clear unmet needs. The company's lead product candidate, Resunab, is a first-in-class, synthetic oral endocannabinoid-mimetic drug that targets chronic inflammation and fibrotic processes by triggering an endogenous pathway called "resolution of inflammation." Resunab is currently being evaluated in three separate phase 2 clinical trials for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation and fibrosis drive morbidity and mortality. For more information, visit the company's website at

CymBay Therapeutics, Inc. (CBAY)

CymBay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. The company's portfolio includes arhalofenate, which has shown two therapeutic actions in a single drug in multiple phase II gout studies; and MBX-8025, a potent, selective, orally active PPARδ agonist. A phase II study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has two ongoing clinical studies for MBX-8025. For more information, visit the company's website at

Cytori Therapeutics, Inc. (CYTX)

Cytori Therapeutics, Inc. (NASDAQ: CYTX) is committed to providing patients and physicians around the world with medical technologies, which harness the potential of adult stem and regenerative cells from adipose tissue. The proprietary Cytori Cell Therapy is under evaluation in the U.S. for the treatment of patients with hand and finger involvement due to the autoimmune condition sleroderma, as well as patients with symptomatic knee osteoarthritis. This technology is approved in many countries around the world, and the company has a number of active global partnerships with academic hospitals, companies and government agencies that share its interest in bringing Cytori Cell Therapy to patients in need. For more information, visit the company's website at

DelMar Pharmaceuticals, Inc. (DMPI)

DelMar Pharmaceuticals, Inc. (OTC: DMPI) is a clinical and commercial stage drug development company with a focus on the treatment of cancer. The company is in the midst of conducting clinical trials in the U.S. with its product candidate, VAL-083, which is designed to serve as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. For more information, visit the company's website at

Galmed Pharmaceuticals (GLMD)

Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical focused on the development and commercialization of therapeutics for the treatment of liver diseases. The company is developing Aramchol, which is in phase 2b clinical trial for the treatment of non-alcoholic steato-hepatitis in patients who also suffer from obesity and insulin resistance. For more information, visit the company's website at

Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is on a quest to expand immune system stimulation to revolutionize the fight against cancers and infectious diseases. Stimulating the body's immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis, and other diseases, and the company's DNA-based immunotherapy technology platform is progressively showing its potential to establish a new paradigm to prevent and treat life-altering diseases, with validating efficacy data from a large controlled phase 2 study. For more information, visit the company's website at

Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma Holdings, Inc. (OTC: MTNB) is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections. The company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, visit the company's website at

Navidea Biopharmaceuticals (NAVB)

Navidea Biopharmaceuticals (NASDAQ: NAVB) envisions a world where disease can be precisely identified and treated. Navidea is a leader in precision medicine with products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying its Manocept technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. For more information, visit the company's website at

NephroGenex, Inc. (NRX)

NephroGenex, Inc. (NASDAQ: NRX) is an innovator in the development of drugs to treat kidney disease with a first indication in diabetic nephropathy. It has been pioneering the development of PYRIDORIN (pyridoxamine dihydrochloride), a late stage compound to treat the one-third of diabetics with this slow-developing but potentially deadly disease. The drug is designed to scavenge a broad range of the pathogenic oxidative chemistries that are elevated in diabetics and cause kidney damage in order to slow/stabilize the progression of end-stage renal disease. For more information, visit the company's website at

Neuralstem, Inc. (CUR)

Neuralstem, Inc.'s (NASDAQ: CUR) patented technology enables the commercial-scale production of multiple types of central nervous system (CNS) stem cells, which are being developed as potential therapies for many CNS diseases and conditions. The company has completed phase 1a and phase 1b trials of NSI-189 for the treatment of major depressive disorder (MDD), and expects to initiate a phase 2 study next year. Neuralstem's first stem cell product candidate, NSI-566, is under development for treatment of amyotrophic lateral sclerosis (ALS); in a phase 1 study to treat paralysis due to chronic spinal cord injury; and in a phase 1 study to treat paralysis from ischemic stroke. Its next generation stem cell product, NSI-532.IGF, is currently in early investigation for Alzheimer's disease (AD). For more information, visit the company's website at

Protea Biosciences Group, Inc. (PRGB)

Protea Biosciences Group, Inc. (OTC: PRGB) is a provider of innovative bioanalytical solutions to the pharmaceutical and life science industries. The company applies its proprietary technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules, which are the byproducts of all living cells and life forms. Protea leads the field in mass spectrometry imaging services (MSI), providing a revolutionary capability that enables the identification and spatial display of biologically-active molecules in tissue and cells. MSI can be performed without sample preparation, labeling or antibody techniques, integrating for the first time direct identification of molecules with anatomic pathology. For more information, visit the company's website at

Sevion Therapeutics, Inc. (SVON)

Sevion Therapeutics, Inc. (OTC: SVON) discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. Sevion's antibody pipeline is being developed from technology that allows for the discovery of innovative biologic therapies to previously inaccessible targets, such as multi-spanning membrane proteins and ion channels that play an important role in multiple diseases. For more information, visit the company's website at

Stellar Biotechnologies, Inc. (SBOTF)

Stellar Biotechnologies, Inc. (OTC: SBOTF) is the leading manufacturer of sustainable keyhole limpet hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Through a recently executed strategic collaboration, the company has established itself as the only KLH supplier with a reliable and scalable source of this vital nutrient. By leveraging its portfolio of proprietary harvesting methods and technologies, the company is committed to meeting the rapidly expanding demand for commercial-scale supplies of GMP-grade KLH. For more information, visit the company's website at

Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is focused on the invention and development of novel pharmaceutical products for medical conditions that it believes have broad societal impact, and that are not well served by currently available therapies. Tonix's Tonmya™ is currently being evaluated in the phase 3 AFFIRM study in fibromyalgia. TNX-102 SL, the same proprietary product candidate as Tonmya, is currently being evaluated in the phase 2 AtEase study in post-traumatic stress disorder. A phase 2 proof-of-concept study of TNX-201 in episodic tension-type headache is ongoing. For more information, visit the company's website at


For more frequent updates, follow us on Twitter!

Home     About Us     IR Services     Investors     Partners     Market Research     Blog     Contact     Disclaimer

© 2016 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975